Search

Displaying results 1931 - 1940 of 10000 in total
  1. Drug

    Siramesine

    go.drugbank.com/drugs/DB06555
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan is an intravenous endothelin receptor A/B antagonist.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    It was investigated as a potential treatment for various pain conditions. … Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  4. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression

    Categories: Histocompatibility Antigens Class I
  5. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  6. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  7. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  8. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D). … [A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on

  10. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide